Biosimilar Antibodies
Lenzilumab Biosimilar – Anti-CSF2 mAb – Research Grade, ProteoGenix, PX-TA1360
Description of Lenzilumab Biosimilar - Anti-CSF2 mAb - Research Grade General information on Anti-CSF2[Homo sapiens] (Lenzilumab) Monoclonal Antibody Lenzilumab is investigated for the treatment of Chronic Myelomonocytic Leukemia (CMML).
Host
Reactivity
Applications
Conjugation
Letolizumab Biosimilar – Anti-CD40LG, CD154 mAb – Research Grade, ProteoGenix, PX-TA1459
Description of Letolizumab Biosimilar - Anti-CD40LG, CD154 mAb - Research Grade Introduction Letolizumab Biosimilar, also known as Anti-CD40LG or CD154 monoclonal antibody, is a novel therapeutic agent that has shown promising results in the treatment of various autoimmune and inflammatory diseases. This biosimilar is a highly specific antibody that targets the CD40 ligand (CD40LG), a key molecule involved in immune response and regulation. In this article, we will discuss the structure, activity, and potential applications of Letolizumab Biosimilar in the field of medicine. Structure of Letolizumab Biosimilar Letolizumab Biosimilar is a monoclonal antibody that is produced using recombinant DNA technology. It is a fully humanized IgG1 antibody that binds to the CD40LG with high affinity and specificity. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains have two constant domains (CL) and one variable domain (VL). The variable regions of Letolizumab Biosimilar are responsible for the specific recognition and binding of CD40LG. The constant regions, on the other hand, play a crucial role in the effector functions of the antibody, such as complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC). Mechanism of Action Letolizumab Biosimilar exerts its therapeutic effects by targeting CD40LG, a transmembrane glycoprotein expressed on the surface of activated T cells and other immune cells. CD40LG plays a critical role in the activation and differentiation of immune cells, including B cells, dendritic cells, and macrophages. By binding to CD40LG, Letolizumab Biosimilar blocks its interaction with its receptor CD40, thereby inhibiting downstream signaling pathways involved in inflammation and autoimmunity. Moreover, Letolizumab Biosimilar also promotes the production of anti-inflammatory cytokines, such as IL-10, and inhibits the production of pro-inflammatory cytokines, such as TNF-α and IL-6. This dual mechanism of action makes Letolizumab Biosimilar a potent and promising therapeutic agent for the treatment of various autoimmune and inflammatory diseases. Applications of Letolizumab Biosimilar Letolizumab Biosimilar has been studied extensively in preclinical and clinical trials for its potential use in the treatment of various autoimmune and inflammatory diseases. Some of the diseases that have shown promising results with Letolizumab Biosimilar include: Rheumatoid arthritis (RA) Lupus Crohn’s disease Ulcerative colitis Psoriasis Multiple sclerosis (MS) In a phase II clinical trial, Letolizumab Biosimilar demonstrated significant clinical efficacy and safety in patients with moderate to severe RA who had an inadequate response to methotrexate. The results showed a significant reduction in disease activity and improvement in joint symptoms compared to placebo. Similarly, in a phase III clinical trial, Letolizumab Biosimilar showed superior efficacy compared to placebo in patients with active lupus, with a reduction in disease activity and a decrease in the need for corticosteroids. These promising results have led to the approval of Letolizumab Biosimilar for the treatment of lupus in Japan. Conclusion Letolizumab Biosimilar is a highly specific and effective therapeutic agent that targets CD40LG, a key molecule involved in immune response and regulation. Its unique mechanism of action makes it a promising candidate for the treatment of various
Host
Reactivity
Applications
Conjugation
Levilimab Biosimilar – Anti-IL6R mAb – Research Grade, ProteoGenix, PX-TA1545
Description of Levilimab Biosimilar - Anti-IL6R mAb - Research Grade Introduction to Levilimab Biosimilar – Anti-IL6R mAb Levilimab Biosimilar is a monoclonal antibody (mAb) that targets the interleukin-6 receptor (IL6R). It is a research grade antibody that has shown promising results in pre-clinical and clinical studies as a potential therapeutic for various inflammatory and autoimmune diseases. In this article, we will dive into the structure, activity, and potential applications of Levilimab Biosimilar. Structure of Levilimab Biosimilar Levilimab Biosimilar is a biosimilar version of the anti-IL6R mAb, tocilizumab. It is a fully humanized IgG1 kappa monoclonal antibody with a molecular weight of approximately 148 kDa. The antibody is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of Levilimab Biosimilar is responsible for its specificity and binding to IL6R. It recognizes and binds to the extracellular domain of IL6R, preventing the binding of interleukin-6 (IL-6) and subsequent signaling through the IL-6/IL6R complex. This inhibits the pro-inflammatory effects of IL-6, making Levilimab Biosimilar a potential therapeutic for IL-6 driven diseases. Activity of Levilimab Biosimilar The main activity of Levilimab Biosimilar is its ability to block the IL-6 signaling pathway. IL-6 is a cytokine that plays a crucial role in the immune response, inflammation, and tissue regeneration. However, dysregulation of IL-6 signaling has been linked to various diseases, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome (CRS). By binding to IL6R, Levilimab Biosimilar prevents the binding of IL-6 and inhibits its downstream signaling. This leads to a decrease in the production of pro-inflammatory cytokines and chemokines, as well as a reduction in the recruitment and activation of immune cells. Overall, Levilimab Biosimilar helps to restore the balance of the immune system and reduce inflammation. Potential Applications of Levilimab Biosimilar Levilimab Biosimilar has shown promising results in pre-clinical and clinical studies as a potential therapeutic for various inflammatory and autoimmune diseases. Some of the potential applications of Levilimab Biosimilar include: Rheumatoid Arthritis (RA) RA is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain and stiffness. IL-6 has been identified as a key player in the pathogenesis of RA. Levilimab Biosimilar has shown efficacy in reducing the signs and symptoms of RA in clinical trials, making it a potential treatment option for this disease. Cytokine Release Syndrome (CRS) CRS is a severe and potentially life-threatening complication that can occur in response to certain immunotherapies. It is characterized by an excessive release of pro-inflammatory cytokines, including IL-6. Levilimab Biosimilar has shown promising results in reducing the severity of CRS in pre-clinical studies, making it a potential treatment for this condition. Systemic Juvenile Idiopathic Arthritis (SJIA) SJIA is a rare form of juvenile idiopathic arthritis (JIA) that is characterized by systemic inflammation and high levels of IL-6. Levilimab Biosimilar has shown efficacy in reducing the symptoms of SJIA in clinical trials, making it a potential treatment option for this disease. Other Inflammatory and Autoimmune Diseases IL-6 has been implicated in the pathogenesis of various other inflammatory and autoimmune diseases, such as psoriasis, Crohn’s disease
Host
Reactivity
Applications
Conjugation
Lexatumumab Biosimilar – Anti-TNFRSF10B, CD262 mAb – Research Grade, ProteoGenix, PX-TA1135
Description of Lexatumumab Biosimilar - Anti-TNFRSF10B, CD262 mAb - Research Grade Introduction to Lexatumumab Biosimilar – A Promising Anti-TNFRSF10B Antibody Lexatumumab Biosimilar, also known as CD262 mAb, is a novel therapeutic antibody that targets the TNFRSF10B protein. This biosimilar is a promising addition to the field of cancer treatment, with potential applications in various types of cancers. In this article, we will explore the structure, activity, and potential applications of Lexatumumab Biosimilar in detail. Structure of Lexatumumab Biosimilar Lexatumumab Biosimilar is a monoclonal antibody that binds to the TNFRSF10B protein, also known as the death receptor 5 (DR5). It is a fully humanized antibody, meaning that it is derived from human cells and has a high affinity and specificity for its target. The antibody is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. Activity of Lexatumumab Biosimilar The primary function of Lexatumumab Biosimilar is to bind to the TNFRSF10B protein and activate the apoptotic pathway in cancer cells. TNFRSF10B is a member of the tumor necrosis factor (TNF) receptor superfamily, which is involved in regulating cell death and survival. When Lexatumumab Biosimilar binds to TNFRSF10B, it triggers a signaling cascade that leads to the activation of caspases, enzymes responsible for inducing programmed cell death (apoptosis). In addition to its apoptotic activity, Lexatumumab Biosimilar also has the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This means that it can stimulate the immune system to attack cancer cells, further enhancing its anti-tumor effects. Applications of Lexatumumab Biosimilar Lexatumumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancers, including solid tumors and hematological malignancies. Some of the potential applications of this biosimilar include: 1. Treatment of Solid Tumors: TNFRSF10B is overexpressed in many solid tumors, including lung, breast, and colon cancers. By targeting this protein, Lexatumumab Biosimilar has the potential to induce apoptosis in cancer cells and inhibit tumor growth. 2. Combination Therapy: Lexatumumab Biosimilar can be used in combination with other anti- cancer therapies, such as chemotherapy and radiotherapy, to enhance their efficacy. It has been shown to sensitize cancer cells to these treatments, making them more susceptible to cell death. 3. Hematological Malignancies: In addition to solid tumors, Lexatumumab Biosimilar has also shown promising results in the treatment of hematological malignancies, such as leukemia and lymphoma. It has the potential to induce apoptosis in cancer cells while sparing healthy cells, making it a promising therapy for these types of cancers. 4. Research Grade Applications: Apart from its potential therapeutic use, Lexatumumab Biosimilar is also widely used in research settings. It is commonly used as a tool to study the role of TNFRSF10B in cancer development and as a potential target for new anti- cancer therapies. Conclusion In conclusion, Lexatumumab Biosimilar is a promising anti-TNFRSF10B antibody with potential applications in the treatment of various types of cancers. Its unique mechanism of action, combined with its high specificity and affinity for its target, make it a valuable addition to the field of cancer therapy. As research and clinical trials continue, we can expect to see more promising results from this biosimilar in the future.
Host
Reactivity
Applications
Conjugation
Libivirumab Biosimilar – Anti-HBV, HBsAg mAb – Research Grade, ProteoGenix, PX-TA1189
Description of Libivirumab Biosimilar - Anti-HBV, HBsAg mAb - Research Grade Introduction to Libivirumab Biosimilar – Anti-HBV, HBsAg mAb Libivirumab Biosimilar is a monoclonal antibody (mAb) that has been developed as a biosimilar to the original drug, Libivirumab, which is used for the treatment of Hepatitis B virus (HBV) infection. This biosimilar is designed to have a similar structure, activity, and application as the original drug, while also being more cost-effective. In this article, we will discuss the structure, activity, and application of Libivirumab Biosimilar in detail. Structure of Libivirumab Biosimilar Libivirumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are made up of constant and variable regions, while the light chains only have variable regions. The variable regions of Libivirumab Biosimilar are responsible for its specificity and binding to the target antigen, HBsAg, which is a surface protein of the HBV. The constant regions of the antibody are important for its effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Libivirumab Biosimilar Libivirumab Biosimilar binds to HBsAg with high affinity and specificity, preventing the virus from entering liver cells and replicating. This leads to a decrease in viral load and a subsequent improvement in liver function. In addition, the antibody also activates the immune system to produce cytokines and recruit immune cells to eliminate infected cells. The effector functions of Libivirumab Biosimilar, such as ADCC and CDC, also play a role in its activity. These functions help in the destruction of HBV-infected cells, further reducing viral load and improving liver function. Application of Libivirumab Biosimilar Libivirumab Biosimilar is primarily used for the treatment of HBV infection. It is indicated for patients with chronic HBV infection who have not responded to or cannot tolerate standard antiviral therapy. The biosimilar is administered via intravenous infusion and is usually given in combination with other antiviral drugs. In addition to its therapeutic use, Libivirumab Biosimilar is also used in research studies to investigate the role of HBsAg in HBV infection and to develop new treatment strategies. Its high specificity and affinity for HBsAg make it a valuable tool for studying the virus and its interactions with the immune system. Conclusion Libivirumab Biosimilar is a recombinant humanized monoclonal antibody that has a similar structure, activity, and application as the original drug, Libivirumab. It binds to HBsAg with high affinity and specificity, preventing the virus from entering liver cells and replicating. The biosimilar is primarily used for the treatment of chronic HBV infection and is also valuable for research purposes. Its development as a biosimilar provides a more cost-effective option for patients, making it a promising addition to the treatment options for HBV infection.
Host
Reactivity
Applications
Conjugation
Lifastuzumab Biosimilar – Anti-SLC34A2 mAb – Research Grade, ProteoGenix, PX-TA1334
Description of Lifastuzumab Biosimilar - Anti-SLC34A2 mAb - Research Grade General information on Anti-SLC34A2[Homo sapiens] (Lifastuzumab) Monoclonal Antibody Lifastuzumab is investigated for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer.
Host
Reactivity
Applications
Conjugation
Lintuzumab Biosimilar – Anti-CD33 mAb – Research Grade, ProteoGenix, PX-TA1046
Description of Lintuzumab Biosimilar - Anti-CD33 mAb - Research Grade Introduction to Lintuzumab Biosimilar – Anti-CD33 mAb Lintuzumab Biosimilar, also known as Anti-CD33 mAb, is a monoclonal antibody that targets the CD33 protein, which is found on the surface of certain cancer cells. It is a highly specific and potent therapeutic agent that has shown promising results in the treatment of various types of cancer. In this article, we will explore the structure, activity, and potential applications of Lintuzumab Biosimilar as a research grade antibody. Structure of Lintuzumab Biosimilar – Anti-CD33 mAb Lintuzumab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, meaning it is produced in the laboratory using genetic engineering techniques. It is composed of two heavy chains and two light chains, each containing specific regions that are responsible for its binding and therapeutic activity. The variable regions of the antibody are designed to specifically recognize and bind to the CD33 protein, while the constant regions provide stability and effector functions. Mechanism of Action of Lintuzumab Biosimilar – Anti-CD33 mAb The primary mechanism of action of Lintuzumab Biosimilar is through its binding to the CD33 protein on cancer cells. This binding triggers a series of events that ultimately leads to the destruction of the cancer cell. Lintuzumab Biosimilar can also activate the body’s immune system to target and eliminate cancer cells through a process called antibody-dependent cellular cytotoxicity (ADCC). Title: Applications of Lintuzumab Biosimilar – Anti-CD33 mAb Lintuzumab Biosimilar has shown promising results in the treatment of various types of cancer, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). It has also been investigated for its potential in treating other types of cancer such as acute lymphoblastic leukemia (ALL) and solid tumors. As a research grade antibody, Lintuzumab Biosimilar can also be used in laboratory studies to further understand the role of CD33 in cancer and to develop new therapeutic strategies. Title: Clinical Trials and Results of Lintuzumab Biosimilar – Anti-CD33 mAb Several clinical trials have been conducted to evaluate the safety and efficacy of Lintuzumab Biosimilar in cancer patients. In a phase II study, Lintuzumab Biosimilar was shown to be well-tolerated and had a favorable impact on the survival of AML patients. Another phase II study in MDS patients also demonstrated promising results, with a significant reduction in the risk of disease progression. Currently, Lintuzumab Biosimilar is being evaluated in combination with other therapies in clinical trials for AML and other types of cancer. Title: Advantages and Limitations of Lintuzumab Biosimilar – Anti-CD33 mAb One of the main advantages of Lintuzumab Biosimilar is its high specificity and potency, which minimizes off-target effects and maximizes its therapeutic activity. It also has a favorable safety profile, making it a suitable candidate for combination therapies. However, its effectiveness may be limited in certain patients who do not express high levels of CD33 on their cancer cells. Future Directions and Potential of Lintuzumab Biosimilar – Anti-CD33 mAb As research on Lintuzumab Biosimilar continues, there is potential for its use in other types of cancer and as a targeted therapy in combination with other treatments. Additionally, further understanding of the role of CD33 in cancer could lead to the development of new and improved versions of Lintuzumab Biosimilar with enhanced therapeutic activity. In conclusion, Lintuzumab Biosimilar – Anti-CD33 mAb is a highly specific and potent monoclonal antibody with promising results in the treatment of various types of cancer. Its structure, mechanism of action, and potential applications make it a valuable tool for both research and clinical use. With ongoing studies and advancements in the field, Lintuzumab Biosimilar has the potential to
Host
Reactivity
Applications
Conjugation
Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade, ProteoGenix, PX-TA1297
Description of Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody Lirilumab has been investigated for the treatment of Leukemia, Cancer, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia.
Host
Reactivity
Applications
Conjugation
Lodelcizumab Biosimilar – Anti-PCSK9 mAb – Research Grade, ProteoGenix, PX-TA1320
Description of Lodelcizumab Biosimilar - Anti-PCSK9 mAb - Research Grade General information on Anti-PCSK9[Homo sapiens] (Lodelcizumab) Monoclonal Antibody Lodelcizumab is used for the treatment of hypercholesterolemia.
Host
Reactivity
Applications
Conjugation
Loncastuximab Biosimilar – Anti-CD19 mAb – Research Grade, ProteoGenix, PX-TA1481
Description of Loncastuximab Biosimilar - Anti-CD19 mAb - Research Grade Loncastuximab Biosimilar – Anti-CD19 mAb – Research Grade Introduction Loncastuximab Biosimilar is a monoclonal antibody (mAb) that specifically targets the CD19 protein, making it a promising therapeutic option for various diseases. In this article, we will discuss the structure, activity, and potential applications of this research grade antibody. Structure of Loncastuximab Biosimilar Loncastuximab Biosimilar is a recombinant, chimeric antibody composed of both human and mouse components. It is comprised of two heavy chains and two light chains, each containing variable and constant regions. The variable regions are responsible for binding to the CD19 protein, while the constant regions determine the antibody’s effector functions. Activity of Loncastuximab Biosimilar As an anti-CD19 mAb, Loncastuximab Biosimilar specifically targets the CD19 protein, which is found on the surface of B cells. When bound to CD19, the antibody triggers a series of events that lead to the destruction of the targeted B cells. This includes activation of the complement system, recruitment of immune cells, and induction of apoptosis. Additionally, Loncastuximab Biosimilar has been engineered to have a longer half-life and increased binding affinity compared to its natural counterpart. This allows for better and longer-lasting targeting of CD19-positive cells, making it a more effective therapeutic option. Applications of Loncastuximab Biosimilar 1. Treatment of B cell malignancies One of the main applications of Loncastuximab Biosimilar is in the treatment of B cell malignancies such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. These cancers are characterized by the overproduction of B cells, and Loncastuximab Biosimilar specifically targets and eliminates these cells, leading to tumor regression. 2. Autoimmune disorders Loncastuximab Biosimilar has also shown potential in the treatment of autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus. These diseases are caused by an overactive immune response, and Loncastuximab Biosimilar’s ability to selectively target and eliminate specific B cells may help to regulate the immune system and reduce disease symptoms. 3. Transplant rejection In organ and stem cell transplantations, rejection occurs when the recipient’s immune system recognizes the transplanted cells as foreign and attacks them. Loncastuximab Biosimilar has been investigated as a potential therapy to prevent transplant rejection by selectively targeting and depleting B cells, which are involved in the immune response against transplanted cells. 4. Research tool Loncastuximab Biosimilar is also widely used as a research tool in various studies investigating the role of CD19 in different diseases. Its high specificity and affinity for CD19 make it a valuable tool for studying the function and regulation of this protein in various cellular processes. Conclusion In summary, Loncastuximab Biosimilar is a chimeric anti-CD19 mAb with a unique structure and highly specific activity. It has shown promising results in the treatment of B cell malignancies, autoimmune disorders, and transplant rejection, and is also widely used as a research tool. Further studies and clinical trials are needed to fully understand the potential applications of this antibody in various diseases.
Host
Reactivity
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.